Weight-Loss drug tirzepatide may help keep heart rhythm steady after ablation
NCT ID NCT07382024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether tirzepatide, a drug used for diabetes and weight loss, can reduce the return of atrial fibrillation (AFib) after a heart procedure called catheter ablation. Overweight or obese adults with persistent AFib will receive either tirzepatide injections plus standard care, or standard care alone. The main goal is to see if the drug lowers the amount of time spent in AFib three months after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tirzepatide
What this could lead to
If it works, this could point toward a way to lower the chance of AFib returning after ablation and improve weight and metabolic health.
What could go wrong
This is a small, early-phase trial with only 200 participants. The drug may not reduce AFib burden, and side effects like nausea or digestive issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERSISTENT ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Taiwan University Hospital Cardiovascular Center
Taipei, 100, Taiwan